Eli Lilly and Boehringer Ingelheim set their sights on acute heart failure with new Jardiance data
A few months after Eli Lilly and Boehringer Ingelheim broke into the chronic heart failure space with their SGLT2 inhibitor Jardiance, the partners are already plotting an expansion into acute heart failure — and on Sunday, they read out some pivotal results to back their bid.
Acute heart failure patients were 36% more likely to benefit from Jardiance than placebo after 90 days (p=0.0054), meeting the primary endpoint in the Phase III EMPULSE trial, Lilly and BI announced at this year’s American Heart Association conference.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
